Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief medical officer Marie-Louise Fjällskog speaks to Proactive about a study into its immunotherapy antibody bexmarilimab as a treatment for blood cancers.
The BEXMAB trial is testing for safety and tolerability but one patient also showed efficacy benefits.
Fjällskog describes the first indications from the study as "super exciting" and "very important for Faron," adding that the next trials will look at dose optimisation and combinations with other drugs.